TrialKPL-301 for Subjects With Giant Cell Arteritis
Trial details
- Registry ID
- NCT03827018
- Phase
- Phase 2
KNSA
Kiniksa Pharmaceuticals, Ltd.
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
0Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| KPL-301 for Subjects With Giant Cell ArteritisNCT03827018 | Kiniksa Pharmaceuticals, Ltd. | Phase 2 | Completed | 2020-08-13Actual |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase InhibitorNCT05198310 | Kiniksa Pharmaceuticals, Ltd. | Phase 2 | Completed | 2024-02-08Actual |
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Trial details
- Registry ID
- NCT05198310
- Phase
- Phase 2
Latest recorded trial changes
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.